Dual Anti‐Platelet Therapy for Carotid Artery Stenosis Has No Significant Advantage Over Monotherapy for Prevention of Stroke – Results from a Large Electronic Database

1Case Western Reserve University (MetroHealth campus), Cleveland, OH
2Beth Israel Deaconess Medical Center, Boston, MA

Meeting: Hospital Medicine 2014, March 24-27, Las Vegas, Nev.

Abstract number: 69

Background:

Secondary prevention of stroke in patients newly diagnosed with carotid artery stenosis remains a challenge. Several studies have reported the use of single as well as dual antiplatelet therapy in patients with stroke, but the rationale for it’s use in patients with carotid artery stenosis remains to be explored. Efficacy of dual anti‐platelet therapy in symptomatic as well as asymptomatic patients with carotid artery stenosis is not yet well defined. The purpose of our study was to compare the incidence of stroke and/ or transient ischemic attack (TIA) over a period of two years in patients diagnosed with carotid stenosis in those on aspirin alone to those on aspirin as well as clopidogrel.

Methods:

The Explorys database, an open access private cloud platform registry which integrates electronic non‐identified patient data of 13 major healthcare systems comprising 31 million patients across 120 hospitals in the United States was used. Patients diagnosed with carotid artery stenosis during 2009 and 2010 were identified using ICD‐9 codes. Patients on aspirin alone were compared to patients on both aspirin and clopidogrel for recurrent stroke and/ or TIA by 2011 and 2012.

Results:

We identified 23,050 patients with carotid artery stenosis and aspirin use alone and compared it with 8,000 patients with carotid stenosis on both aspirin and clopidogrel. The rates of occurrence of stroke and/ or TIA were not significantly different in between the two groups over a period of two years (6.8% versus 6.5%; p= 0.32). However the incidence of major and/or minor bleeding were significantly higher in the dual anti‐platelet group (14.4% versus 16.4%; p=0.003). The results are summarised in the figure 1.

Conclusions:

Evidence for efficacy of dual antiplatelet therapy in carotid artery stenosis for secondary prevention of stroke is limited. Aspirin is the mainstay of antithrombotic medication in the secondary prevention of non‐cardioembolic stroke and TIA. Dual antiplatelet therapy has no significant benefit for long‐term secondary stroke prevention in carotid stenosis, especially aspirin and clopidogrel, while it could potentially result in greater bleeding complications.

To cite this abstract:

Sengodan P, Ramanujam V, Poongkunran M, Gandhi S. Dual Anti‐Platelet Therapy for Carotid Artery Stenosis Has No Significant Advantage Over Monotherapy for Prevention of Stroke – Results from a Large Electronic Database. Abstract published at Hospital Medicine 2014, March 24-27, Las Vegas, Nev. Abstract 69. Journal of Hospital Medicine. 2014; 9 (suppl 2). https://www.shmabstracts.com/abstract/dual-antiplatelet-therapy-for-carotid-artery-stenosis-has-no-significant-advantage-over-monotherapy-for-prevention-of-stroke-results-from-a-large-electronic-database/. Accessed July 17, 2019.

« Back to Hospital Medicine 2014, March 24-27, Las Vegas, Nev.